Volume Shocker Today, Jan 6, 2026: Aurobindo Pharma Hit Records Highest Single-Day Volume in Almost 2-Months; Here’s Why

Nifty Pharma in Spotlight: Top Performing Sector on January 06, 2026

On Tuesday, January 06, 2026, the Nifty Pharma emerged as the top performing sector. It was trading higher by 1.64%, with the majority of its constituents trading in green. However, there was one specific stock pharma sector which managed to hog the limelight was Aurobindo Pharma as price surged was seen along with a jump in volume. 

Aurobindo Pharma Share Price Movement and Volume Buzzer

The Aurobindo Pharma share price gained as much as 1.6% during the session and was trading at ₹1,227.20 per share on the NSE(as of 2:38 pm). The stock hit 4 week high, hovering near the resistance of ₹1,250 per share.

Importantly, the rally was backed by exceptional activity. On January 6, 2026, Aurobindo Pharma recorded record volumes of over 14 lakhs, the highest single-day volume seen in the stock in almost the last two months. The volume recorded on Tuesday is nearly double than its 20-day average volume.

What Does Aurobindo Pharma Do?

Aurobindo Pharma Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs) and generic pharmaceutical formulations. The company produces medicines in oral solids, liquids, and injectable forms, catering to therapeutic areas such as CNS, cardiovascular, antibiotics, anti-retroviral, gastroenterological, anti-diabetic, and anti-allergic drugs. It is one of India’s largest pharma companies by revenue and a leading supplier of generic medicines in the US and European markets.

Aurobindo Pharma Subsidiary Acquires Khandelwal Labs’ Non-Oncology Business for ₹325 Crore

Hyderabad-based Aurobindo Pharma Ltd announced that its wholly owned subsidiary, Auro Pharma Limited, has acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories Private Limited to strengthen its domestic presence.

The acquisition was carried out through a Business Transfer Agreement on a slump sale basis as a going concern. The total cash consideration for the deal stands at ₹325 crore, subject to customary working capital adjustments.

The acquired business has delivered stable revenues over the past three financial years, recording ₹104.98 crore in FY23, ₹114.69 crore in FY24, and ₹113.53 crore in FY25. For FY25, the business reported an EBITDA of ₹28.99 crore.

Through this acquisition, Aurobindo Pharma gains exposure to the anti-infective and pain management segments. The transaction includes 23 marketed brands spanning 67 SKUs, nine products in the pipeline, a distribution network of over 1,600 stockists, and a field force of around 470 employees.

Aurobindo said the acquired portfolio will complement its existing product range and support faster growth in the domestic formulations market. The deal also includes the transfer of intellectual property, inventory, and all related contracts.

How has Aurobindo Pharma’s Share Price Performed?

Aurobindo Pharma shares have delivered strong gains: 

• Up 2.15% in the last one week
• Up 12.5% in the last three months